• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

霉酚酸酯对系统性红斑狼疮非肾脏表现的影响:韩国狼疮网络注册研究结果。

The Effect of Mycophenolate Mofetil on Non-Renal Manifestations in Systemic Lupus Erythematosus: Results from Korean Lupus Network Registry.

机构信息

Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea.

Department of Medical Statistics, Catholic University of Daegu School of Medicine, Daegu, Korea.

出版信息

J Korean Med Sci. 2019 Jul 15;34(27):e185. doi: 10.3346/jkms.2019.34.e185.

DOI:10.3346/jkms.2019.34.e185
PMID:31293110
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6624417/
Abstract

BACKGROUND

The objective of this study was to identify the effects of mycophenolate mofetil (MMF) on non-renal manifestations in systemic lupus erythematosus (SLE).

METHODS

The study population comprised 439 SLE patients from the Korean Lupus Network registry who were followed up annually and completed the baseline survey and two follow-up visits from 2014 to 2018. Disease activity, laboratory markers, and clinical manifestations including mucocutaneous lesions, arthritis, serositis, neurological disorders, and hematologic/immunologic abnormalities were assessed. All variables by group (MMF and non-MMF) effects with time (baseline, 1st follow-up, and 2nd follow-up) were analyzed by generalized estimation equation.

RESULTS

Seventy-two patients were treated with MMF. There was significant difference in frequencies of malar rash, arthritis, renal disorder, and hematologic disorder between MMF and non-MMF groups in total SLE patients. In subgroup analysis of hematologic abnormalities in total patients, frequency of leukopenia was significantly different between the two groups during follow-up ( = 0.001), but frequencies of hemolytic anemia, lymphopenia, and thrombocytopenia were not. In addition, frequencies of leukopenia in patients without lupus nephritis were significantly decreased in MMF group compared to non-MMF group ( = 0.012).

CONCLUSION

This study showed that MMF might be a beneficial treatment for hematologic abnormalities, especially leukopenia, in SLE.

摘要

背景

本研究旨在探讨霉酚酸酯(MMF)对系统性红斑狼疮(SLE)非肾脏表现的影响。

方法

该研究纳入了 2014 年至 2018 年期间韩国狼疮网络注册中心的 439 例 SLE 患者,这些患者每年接受随访,并完成了基线调查和两次随访。评估疾病活动、实验室标志物以及包括黏膜皮肤损伤、关节炎、浆膜炎、神经病变和血液/免疫异常在内的临床表现。采用广义估计方程分析按组(MMF 和非 MMF)和时间(基线、第 1 次随访和第 2 次随访)划分的所有变量的效应。

结果

72 例患者接受 MMF 治疗。在总 SLE 患者中,MMF 组和非 MMF 组在蝶形红斑、关节炎、肾脏疾病和血液疾病方面的发生率存在显著差异。在总患者血液异常亚组分析中,两组在随访期间白细胞减少的发生率存在显著差异( = 0.001),但溶血性贫血、淋巴细胞减少和血小板减少的发生率无差异。此外,在无狼疮肾炎的患者中,MMF 组的白细胞减少发生率明显低于非 MMF 组( = 0.012)。

结论

本研究表明,MMF 可能对 SLE 的血液异常,特别是白细胞减少症有治疗作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e4/6624417/50cd7d4aabde/jkms-34-e185-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e4/6624417/50cd7d4aabde/jkms-34-e185-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e4/6624417/50cd7d4aabde/jkms-34-e185-g001.jpg

相似文献

1
The Effect of Mycophenolate Mofetil on Non-Renal Manifestations in Systemic Lupus Erythematosus: Results from Korean Lupus Network Registry.霉酚酸酯对系统性红斑狼疮非肾脏表现的影响:韩国狼疮网络注册研究结果。
J Korean Med Sci. 2019 Jul 15;34(27):e185. doi: 10.3346/jkms.2019.34.e185.
2
Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.霉酚酸酯在日本系统性红斑狼疮患者中的疗效。
Clin Rheumatol. 2019 Jun;38(6):1571-1578. doi: 10.1007/s10067-019-04473-w. Epub 2019 Feb 18.
3
Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review.霉酚酸酯治疗系统性红斑狼疮的非肾脏表现:一项系统评价
Scand J Rheumatol. 2007 Sep-Oct;36(5):329-37. doi: 10.1080/03009740701607042.
4
Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus.霉酚酸酯治疗系统性红斑狼疮难治性溶血性贫血
Lupus. 2005;14(10):856-8. doi: 10.1191/0961203305lu2163cr.
5
Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study.119 例日本系统性红斑狼疮患者吗替麦考酚酯安全性的真实世界经验:一项回顾性单中心研究。
Biomed Res Int. 2021 Jan 23;2021:8630596. doi: 10.1155/2021/8630596. eCollection 2021.
6
Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study.霉酚酸酯治疗系统性红斑狼疮的非肾脏表现:一项观察性队列研究
J Rheumatol. 2016 Mar;43(3):552-8. doi: 10.3899/jrheum.150779. Epub 2016 Jan 15.
7
Mycophenolate mofetil and systemic lupus erythematosus: an overview.霉酚酸酯与系统性红斑狼疮:概述
Lupus. 2005;14 Suppl 1:s9-11. doi: 10.1191/0961203305lu2111oa.
8
Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years.霉酚酸酯能否预防系统性红斑狼疮的肾外发作?一项针对单一医疗机构中接受长达5年治疗的患者的观察性研究结果。
Lupus. 2009 May;18(6):516-21. doi: 10.1177/0961203308099471.
9
Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus: A Randomized Clinical Trial.霉酚酸酯与新发系统性红斑狼疮:一项随机临床试验
JAMA Netw Open. 2024 Sep 3;7(9):e2432131. doi: 10.1001/jamanetworkopen.2024.32131.
10
Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature.霉酚酸酯治疗系统性红斑狼疮:一项大型单中心队列回顾性研究结果及文献综述
Immunol Res. 2014 Dec;60(2-3):270-6. doi: 10.1007/s12026-014-8609-x.

引用本文的文献

1
A Real-World Experience of Mycophenolate Mofetil for Systemic Sclerosis: A Retrospective Multicenter Observational Study.霉酚酸酯治疗系统性硬化症的真实世界经验:一项回顾性多中心观察性研究。
Arch Rheumatol. 2020 Jan 13;35(3):366-375. doi: 10.46497/ArchRheumatol.2020.7771. eCollection 2020 Sep.
2
Are lupus animal models useful for understanding and developing new therapies for human SLE?狼疮动物模型对于理解和开发人类 SLE 的新疗法是否有用?
J Autoimmun. 2020 Aug;112:102490. doi: 10.1016/j.jaut.2020.102490. Epub 2020 Jun 11.

本文引用的文献

1
Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.霉酚酸酯在日本系统性红斑狼疮患者中的疗效。
Clin Rheumatol. 2019 Jun;38(6):1571-1578. doi: 10.1007/s10067-019-04473-w. Epub 2019 Feb 18.
2
One year in review 2018: systemic lupus erythematosus.2018 年回顾:系统性红斑狼疮。
Clin Exp Rheumatol. 2018 Sep-Oct;36(5):763-777. Epub 2018 Sep 26.
3
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults.英国风湿病学会成人系统性红斑狼疮管理指南。
Rheumatology (Oxford). 2018 Jan 1;57(1):e1-e45. doi: 10.1093/rheumatology/kex286.
4
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives.神经精神性系统性红斑狼疮的管理:当前方法与未来展望
Drugs. 2016 Mar;76(4):459-83. doi: 10.1007/s40265-015-0534-3.
5
Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study.霉酚酸酯治疗系统性红斑狼疮的非肾脏表现:一项观察性队列研究
J Rheumatol. 2016 Mar;43(3):552-8. doi: 10.3899/jrheum.150779. Epub 2016 Jan 15.
6
Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.在临床试验、长期观察性研究和临床护理中评估系统性红斑狼疮患者的指标。
Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-85-95. Epub 2014 Oct 30.
7
Systemic lupus erythematosus.系统性红斑狼疮。
Lancet. 2014 Nov 22;384(9957):1878-1888. doi: 10.1016/S0140-6736(14)60128-8. Epub 2014 May 31.
8
Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement.开放标签随机对照试验,评估霉酚酸钠与其他传统免疫抑制剂相比,对无肾脏受累的活动性系统性红斑狼疮患者的疗效。
Int J Rheum Dis. 2013 Dec;16(6):724-30. doi: 10.1111/1756-185X.12179. Epub 2013 Oct 14.
9
Systemic lupus erythematosus.系统性红斑狼疮
N Engl J Med. 2011 Dec 1;365(22):2110-21. doi: 10.1056/NEJMra1100359.
10
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.来氟米特与吗替麦考酚酯治疗狼疮性肾炎的长期免疫抑制作用:来自 MAINTAIN 肾炎试验的结果。
Ann Rheum Dis. 2010 Dec;69(12):2083-9. doi: 10.1136/ard.2010.131995. Epub 2010 Sep 10.